Strong 2Q cash receipts, notes Morgans, resulted in the fourth consecutive quarter of positive net operating cashflow for Volpara Health Technologies.

Average Revenue Per Account (ARPA) was US$40.4k, up from US$39.0k in the 1Q,  and has been growing at a compounding rate of over 20% since 2022, point out the analysts.

The $1.20 target and Add rating are unchanged.

Sector: Health Care Equipment & Services.

Target price is $1.20.Current Price is $0.76. Difference: $0.44 - (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 37% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2023 Acquisdata Pty Ltd., source FN Arena